Author

Nitsan Halevy

Observed name: Halevy, Nitsan

Observed institutions: Brigham and Women's Hospital, Harvard University, Teva Pharmaceuticals (Israel)

OpenAlex ID: A5090023232

Cardiovascular risk indicators and perceived race/ethnic discrimination in the Dallas Heart Study

2008 · Michelle A. Albert, Joseph Ravenell, et al. · American Heart Journal · 65

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

2021 · Giancarlo Comi, Yuval Dadon, et al. · Multiple Sclerosis Journal · 30

PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial

2024 · Lars Norgren, Norbert Weiss, et al. · British journal of surgery · 19

Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study

2023 · Joseph P. McGuirk, Leland Metheny, et al. · Bone Marrow Transplantation · 7

A Single Placenta-Derived Mesenchymal-Like Stromal Cell Injection Halts Progression of Primary Knee Osteoarthritis – First Preclinical Results from the PROTO consortium

2024 · Tazio Maleitzke, Sijia Zhou, et al. · Osteoarthritis and Cartilage · 3

234. Phage Therapy with BX211 Demonstrates Positive Efficacy Results in Staphylococcus Aureus Diabetic Foot Osteomyelitis: Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial

2026 · Benjamin A Lipsky, Ariel Cohen, et al. · Open Forum Infectious Diseases · 2

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study

2024 · Joseph P. McGuirk, Leland Metheny, et al. · Bone Marrow Transplantation · 1

P-1164. Targeting Antibiotic-Resistant and Biofilm-Forming Staphylococcus aureus with BX211 Phage Therapy

2026 · Ariel Cohen, Benjamin A Lipsky, et al. · Open Forum Infectious Diseases

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

2022 · Hillard M Lazarus, Joseph P. McGuirk, et al. · Blood

Works count: 12

Citation count: 127

H-index: 4

I10-index: 3